
    
      This is an open-label, Phase 1a/b dose escalation study of OMP-31M32 administered as a single
      agent or in combination with nivolumab to evaluate the safety, tolerability pharmacokinetics,
      and pharmacodynamics in patients with locally advanced or metastatic solid tumors. This study
      consists of a screening period, a treatment period and a post-treatment follow-up period in
      which patients will be followed for survival for up to 2 years. Subjects will be enrolled in
      two stages in the Phase 1a (dose escalation and expansion) and one stage in the Phase 1b
      (dose escalation).
    
  